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Shortage of vaccines during a yellow
fever outbreak in Guinea
N Nathan, M Barry, M Van Herp, H Zeller
A yellow fever epidemic erupted in Guinea in September, 2000.
From Sept 4, 2000, to Jan 7, 2001, 688 instances of the disease
and  225  deaths  were  reported.  The  diagnosis  was  laboratory
confirmed by IgM detection in more than 40 patients. A mass
vaccination  campaign  was  limited  by  insufficient  international
stocks.  After  the  epidemic  in  Guinea,  the  International
Coordinating Group on Vaccine Provision for Epidemic Meningitis
Control decided that 2 million doses of 17D yellow fever vaccine,
being stored as part of a UNICEF stockpile, should be used only
in response to outbreaks. 
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Yellow fever is a viral haemorrhagic fever that is caused by a
flavivirus  transmitted  by  mosquitoes.  Case-fatality  ratios
(CFR) exceed 50% in severe instances.
1,2 The disease can be
prevented by vaccination with the 17D yellow fever vaccine,
which  protects  for  at  least  10  years.  WHO  estimates  that 
200 000  people  in  34  countries  of  Africa  and  America,  in
which  the  disease  is  endemic  or  occurs  epidemically,  are
infected every year, resulting in 30 000 deaths.
1,2 The disease is
endemic  in  rural  areas  near  tropical  forests,  but  large
epidemics usually arise when a specific vector (Aedes aegypti)
transmits the virus in urban settings. Large outbreaks were
reported in Ethiopia in 1960 (100 000 cases), in Senegal in
1965 (20 000), and in Nigeria in 1969 (100 000).
1,2 Between
1986  and  1994,  more  than  20 000  cases  were  reported  in
successive epidemics in Nigeria. 
In  September,  2000,  a  yellow  fever  epidemic  began  in
Guinea,  where  no  routine  vaccination  or  reactive  mass
vaccination campaigns have been done since the end of the
1950s. From Sept 4, 2000, to Jan 7,2001, 688 cases and 225
deaths were reported (CFR 33%). More than 40 people from
12 different districts had the diagnosis confirmed by ELISA
capture and neutralisation tests (IgM detection). During the
first 7 weeks of the epidemic, the CFR was more than 60%.
However, this rate had fallen by week 42, probably because of
better  diagnosis  of  non-haemorrhagic  disease,  fewer  false
cases, and improved supportive care. The epidemic peaked in
week 47 (between Nov 20 and Nov 26), during which 139
new cases and 46 deaths were reported (figure 1). 
For  the  first  4  weeks,  only  the  Mamou  district  in  the
Mamou  region  was  affected.  The  outbreak  then  spread  to
another 16 of the 33 districts of the country (figure 2) . The
most affected regions were Mamou and Labé, where the alert
was  sounded  on  Oct  12  and  Nov  6,  respectively.  In  these
regions, 80% of individuals with yellow fever lived in rural
areas, and district attack rates ranged from 0·1 to 8·0 cases per
10 000 inhabitants. Entomological investigations done in eight
of the most affected villages identified only one sylvatic vector
breeding site. No A aegypti mosquitoes were found in these
villages. The low density of A aegypti (<5 breeding sites per
100 households) identified in the investigated towns (Labé,
Coya, Conakry) prevented the outbreak from developing in
the urban setting, where only 78 (12% of the total) individuals
in four of the eight main regional cities became ill. 
The  Guinean  Ministry  of  Health,  with  the  support  of
international non-governmental organisations, implemented a
mass vaccination campaign in response to the epidemic. The
initial target population included all individuals aged 9 months
or  older  who  were  living  in  Mamou  district  and  in  four
surrounding unaffected subdistricts (352 278 inhabitants). A
first appeal for vaccines was made on Nov 1, 2000. 10 days
later, 630 000 doses of vaccine were brought into the country,
and vaccination began in Mamou district on Nov 12, 1 week
before the peak of the outbreak in that region. 
After the alert was given in Labé region, the target popula-
tion  was  re-estimated  at  1 679 648  people,  and  a  second
appeal for vaccines was made on Nov 13. However, no more
vaccines arrived in the country until Dec 17 (5 weeks after the
second  appeal),  when  300 000  doses  were  delivered  to
Conakry (figure 1). A further 672 000 doses arrived on Jan 5,
2001, of which 150 000 were sent to Labé region. Vaccines
were brought from Europe, from the Pasteur Dakar institute,
which  held  stocks  of  the  vaccine,  from  national  stocks  in
different countries (ie, Niger, Nigeria, and Ghana), and from
expanded programmes of immunisation (EPI) in the region.
Médecins  Sans  Frontières,  WHO,  and  UNICEF  were  the
main organisations involved in securing the vaccine stocks.
Because  of  the  shortage  of  vaccines,  mass  vaccination
campaigns in Labé did not start until 4 weeks after the peak of
the  epidemic  in  that  region.  Furthermore,  vaccination
strategies had to be revised and target populations restricted to
affected urban areas and to worst affected rural areas. At the
end of the intervention, just 9 weeks later, 856 031 individuals
had been vaccinated in Mamou and Labé, where the overall
vaccine  coverage  was  estimated  at  56%.  The  Ministry  of
Health and MSF continued mass-vaccination campaigns in
other regions and used up the available stocks.
Yellow  fever  epidemics  are  re-emerging  in  Africa  and
America,  and  the  occurrence  of  repeated  rural  outbreaks
increases the risk for major urban epidemics.
3,4 However, as
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Figure 1: Yellow fever cases deaths, and details of vaccinations
Figure 2: Areas affectedFor personal use. Only reproduce with permission from The Lancet Publishing Group.
Blood-pressure reduction and
cardiovascular risk in HOPE study
Peter Sleight, Salim Yusuf, Janice Pogue, Ross Tsuyuki, Rafael Diaz,
Jeffrey Probstfield, for the Heart Outcomes Prevention Evaluation
(HOPE) Study Investigators
In the Heart Outcomes Prevention Evaluation (HOPE) study, use
of the angiotensin-converting-enzyme inhibitor ramipril was asso-
ciated with a 22% relative risk reduction in cardiovascular death,
myocardial infarction, or stroke, despite only a modest reduction
in blood pressure (3·3 mm Hg systolic). To test the hypothesis
that the benefits seen were not due to reduced blood pressure
alone, we calculated blood-pressure-related risk estimates from
the placebo group of the HOPE trial, and from earlier studies. We
found that the benefits seen in HOPE were around three times
greater  than  predicted  from  these  calculations.  In  this  well
treated  and  largely  normotensive  population  with  coronary
disease,  but  good  left-ventricular  function,  the  benefits  from
ramipril were additive to other proven therapies in normotensive
patients and in those with higher baseline blood pressure.
Lancet 2001; 358: 2130–31
Angiotensin-converting-enzyme (ACE) inhibitors lower blood
pressure, but have other potentially protective actions on left-
ventricular  hypertrophy,  endothelial  function,  and  smooth-
muscle growth. In the Heart Outcomes Prevention Evaluation
(HOPE)  study,
1 ramipril  (10  mg  per  day)  lowered  blood
pressure  only  modestly  (by  3·3/1·4  mm  Hg)  in  high-risk,
mostly  normotensive  patients,  but  still  reduced  the  primary
endpoint  (cardiovascular  death,  myocardial  infarction,  or
stroke)  over  4·5  years  by  22%,  independent  of  other
established  treatments  of  known  hypertension.  There  is
controversy about the view that these benefits are not explained
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by the blood-pressure reduction seen. We now present further
analyses  of  the  relation  between  the  observed  benefit  and
baseline  blood  pressure,  and  degree  of  blood  pressure
reduction, together with estimates of what might be expected
from previous data on blood pressure and risk, as well as from
estimates derived from the placebo group of HOPE.
In  HOPE,  blood  pressure  was  measured  in  duplicate  by
trained nurses after 5 min rest at baseline, 1 month, 2 years,
and at study end. We calculated the “usual” blood pressure by
averaging all available blood pressures in the placebo patients
free  of  myocardial  infarction.  By  use  of  a  Cox’s  regression
analysis, we related differences in systolic blood pressure to
differences  in  risk  of  the  primary  outcome  in  our  placebo
group. This estimate of blood-pressure-related risk was also
compared with similar calculations derived from independent
observational  analyses  from  other  studies,  and  that  derived
from  a  meta-analysis  of  all  trials  (referred  to  jointly  as
WHO/ISH  in  table  1).  These  two  independent  blood-
pressure-related risk estimates were then compared with the
observed risk reduction from ramipril. We also compared the
benefits  of  ramipril  above  and  below  the  median  baseline
blood pressure (138 mm Hg systolic and 80 mm Hg diastolic).
The observed benefit from ramipril was much greater than
expected  from  the  blood-pressure  reduction  in  HOPE
(table 1),  estimated  either  from  earlier  studies,  or  from  the
experience in the HOPE placebo-group patients, who were at
higher risk than those in previous hypertension trials.
The relative risk of the primary outcome for ramipril versus
placebo (0·78 [95% CI 0·70–0·86]) did not change after ad-
justment for time-dependent change in systolic blood pressure
and diastolic blood pressure. For each separate component of
the  primary  outcome  (myocardial  infarction,  stroke,  and
cardiovascular  death),  the  unadjusted  and  adjusted  relative
risks were respectively 0·80 (0·70–0·90) and 0·77 (0·65–0·91);
0·68 (0·56–0·84) and 0·72 (0·58–0·89); and 0·74 (0·64–0·87)
and 0·77 (0·65–0·91). Significant benefit was also seen in the
normotensive population comprising those with baseline blood
pressure below the median of 138/80 mm Hg (table 2).
The benefits from ACE inhibition were independent of, and
additive to, those from other proven hypertension therapies.
The  relative  risk  of  the  primary  outcome  with  or  without 
-blockade,  diuretics,  or  calcium-channel  blockers  were,
respectively, 0·77 (0·65–0·90) versus 0·78 (0·68–0·89); 0·75
(0·59–0·94)  versus  0·78  (0·70–0·88);  and  0·84  (0·73–0·97)
versus 0·71 (0·61–0·83). In each of these six comparisons of
ramipril  versus  placebo,  there  was  significant  benefit  from
ramipril for the primary outcome (p<0·01), with no significant
evidence of heterogeneity.
In  a  high-risk  population  (80%  had  previous  coronary
disease, but normal baseline blood pressure and left-ventricular
function), ramipril confers substantial benefits which are addi-
tional  to  those  from  other  antihypertensive  medication 
and  greater  than  expected  from  the  modest  blood-pressure
reduction. These benefits are similar in importance to those of
aspirin and statins in protection against further serious events.
3
There  has  been  speculation  that  the  relatively  few
shown  by  the  Guinean  episode,  the  international  stocks  of
yellow fever vaccines are not sufficient to provide an adequate
and rapid response to large outbreaks. In 2000, an alert was
sounded in Kano city (1·5 million inhabitants), Nigeria. No
epidemic  occurred,  but  had  there  been  one  the  stocks  of
vaccines would not have been adequate (unpublished data,
Epicentre,  July,  2000).  During  the  yellow  fever  consensus
meeting, WHO recommended that an emergency stockpile of
1 million doses be retained in Africa and America for outbreak
response.
2 Furthermore,  after  the  epidemic  in  Guinea,  the
International Coordinating Group on Vaccine Provision for
Epidemic  Meningitis  Control  decided  that  2  million  doses,
being stored as part of a UNICEF stockpile, should be used
only in response to outbreaks. If effective, this stock should
limit shortages of vaccines during future epidemics. However,
prevention of yellow fever epidemics can only be addressed by
organising pre-emptive mass vaccination campaigns or by a
large and effective introduction of yellow fever vaccination in
the EPI of the countries at risk, as recommended by WHO.
1 WHO. Yellow fever: WHO/EPI/GEN/98.11. Geneva: WHO, 1998.
2 WHO. Yellow fever technical consensus meeting: HO/EPI/GEN/98.08.
Geneva: WHO, 1998.
3 WHO. Yellow fever, 1996–1997, part I. Wkly Epidemiol Rec 1998; 73:
354–59.
4 WHO. Yellow fever, 1996 –1997, part II. Wkly Epidemiol Rec 1998; 73:
370–72.
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Data source Difference in  Relative risk reduction
systolic blood
Myocardial  Stroke pressure (mm Hg)
infarction
WHO/ISH* guidelines 10–15 15 40
HOPE
Ramipril group
Estimated† 3·3 5 13
Observed 3·3 20 32
Placebo group 
Estimated 3·3 5·5 7
*International Society of Hypertension. †Derived from WHO/ISH.
Table 1: Estimates of risk reduction for stroke and myocardial
infarction for a given difference in systolic blood pressure